Skip to main content
. 2020 Aug;8(16):1000. doi: 10.21037/atm-20-5298

Figure 4.

Figure 4

Kaplan-Meier estimated progression-free survival (A) and overall survival (B) curves of patients with hepatocellular carcinoma in the sorafenib and apatinib groups.